Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Ivacaftor pharmacokinetics and lymphatic transport after enteral administration in rats

J. Pozniak, P. Ryšánek, D. Smrčka, P. Kozlík, T. Křížek, J. Šmardová, A. Nováková, D. Das, D. Bobek, M. Arora, J. Hofmann, T. Doušová, M. Šíma, O. Slanař

. 2024 ; 15 (-) : 1331637. [pub] 20240220

Status not-indexed Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24005743

Background: Ivacaftor is a modern drug used in the treatment of cystic fibrosis. It is highly lipophilic and exhibits a strong positive food effect. These characteristics can be potentially connected to a pronounced lymphatic transport after oral administration. Methods: A series of studies was conducted to describe the basic pharmacokinetic parameters of ivacaftor in jugular vein cannulated rats when dosed in two distinct formulations: an aqueous suspension and an oil solution. Additionally, an anesthetized mesenteric lymph duct cannulated rat model was studied to precisely assess the extent of lymphatic transport. Results: Mean ± SD ivacaftor oral bioavailability was 18.4 ± 3.2% and 16.2 ± 7.8%, respectively, when administered as an aqueous suspension and an oil solution. The relative contribution of the lymphatic transport to the overall bioavailability was 5.91 ± 1.61% and 4.35 ± 1.84%, respectively. Conclusion: Lymphatic transport plays only a minor role in the process of ivacaftor intestinal absorption, and other factors are, therefore, responsible for its pronounced positive food effect.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24005743
003      
CZ-PrNML
005      
20250715102302.0
007      
ta
008      
240405e20240220sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2024.1331637 $2 doi
035    __
$a (PubMed)38444938
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Pozniak, Jiří $u Third Department of Surgery, First Faculty of Medicine, Motol University Hospital, Charles University, Prague, Czechia
245    10
$a Ivacaftor pharmacokinetics and lymphatic transport after enteral administration in rats / $c J. Pozniak, P. Ryšánek, D. Smrčka, P. Kozlík, T. Křížek, J. Šmardová, A. Nováková, D. Das, D. Bobek, M. Arora, J. Hofmann, T. Doušová, M. Šíma, O. Slanař
520    9_
$a Background: Ivacaftor is a modern drug used in the treatment of cystic fibrosis. It is highly lipophilic and exhibits a strong positive food effect. These characteristics can be potentially connected to a pronounced lymphatic transport after oral administration. Methods: A series of studies was conducted to describe the basic pharmacokinetic parameters of ivacaftor in jugular vein cannulated rats when dosed in two distinct formulations: an aqueous suspension and an oil solution. Additionally, an anesthetized mesenteric lymph duct cannulated rat model was studied to precisely assess the extent of lymphatic transport. Results: Mean ± SD ivacaftor oral bioavailability was 18.4 ± 3.2% and 16.2 ± 7.8%, respectively, when administered as an aqueous suspension and an oil solution. The relative contribution of the lymphatic transport to the overall bioavailability was 5.91 ± 1.61% and 4.35 ± 1.84%, respectively. Conclusion: Lymphatic transport plays only a minor role in the process of ivacaftor intestinal absorption, and other factors are, therefore, responsible for its pronounced positive food effect.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ryšánek, Pavel $u First Faculty of Medicine, Institute of Pharmacology, General University Hospital in Prague, Charles University, Prague, Czechia
700    1_
$a Smrčka, David $u Zentiva, K. S, Prague, Czechia
700    1_
$a Kozlík, Petr $u Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czechia
700    1_
$a Křížek, Tomáš $u Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czechia
700    1_
$a Šmardová, Jaroslava $u First Faculty of Medicine, Institute of Pharmacology, General University Hospital in Prague, Charles University, Prague, Czechia
700    1_
$a Nováková, Anežka $u First Faculty of Medicine, Institute of Pharmacology, General University Hospital in Prague, Charles University, Prague, Czechia
700    1_
$a Das, Debanjan $u First Faculty of Medicine, Institute of Pharmacology, General University Hospital in Prague, Charles University, Prague, Czechia
700    1_
$a Bobek, Daniel $u First Faculty of Medicine, Institute of Pharmacology, General University Hospital in Prague, Charles University, Prague, Czechia
700    1_
$a Arora, Mahak $u First Faculty of Medicine, Institute of Pharmacology, General University Hospital in Prague, Charles University, Prague, Czechia $7 xx0333974
700    1_
$a Hofmann, Jiří $u Zentiva, K. S, Prague, Czechia
700    1_
$a Doušová, Tereza $u Department of Pediatrics, Second Faculty of Medicine, Motol University Hospital, Charles University, Prague, Czechia
700    1_
$a Šíma, Martin $u First Faculty of Medicine, Institute of Pharmacology, General University Hospital in Prague, Charles University, Prague, Czechia
700    1_
$a Slanař, Ondřej $u First Faculty of Medicine, Institute of Pharmacology, General University Hospital in Prague, Charles University, Prague, Czechia
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 15 (20240220), s. 1331637
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38444938 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240405 $b ABA008
991    __
$a 20250715102247 $b ABA008
999    __
$a ok $b bmc $g 2076010 $s 1215505
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 15 $c - $d 1331637 $e 20240220 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
LZP    __
$a Pubmed-20240405

Find record

Citation metrics

Archiving options